Therapeutic targets and novel anticancer agents for endocrine cancers

背景：甲状腺癌：甲状腺癌的发病率在过去二十年中翻了一番。虽然大多数滤泡细胞来源的甲状腺癌患者预后良好，但10% - 15%的患者对常规治疗（切除联合放射性碘消融和甲状腺激素抑制TSH）难以治疗。化疗和外照射对转移性疾病患者无效。滤泡细胞来源的转移性甲状腺癌患者的总体10年生存率约为40- 50%。甲状腺未分化癌是目前尚无有效系统治疗的最致命的实体恶性肿瘤之一。肾上腺皮质癌：大约三分之二的肾上腺皮质癌患者有局部疾病和转移。不幸的是，尽管采用了综合治疗，肾上腺皮质癌患者的总体预后仍然很差，5年生存率低于35%。总结：我们已经完成了对4，292种新组装的化合物的定量高通量筛选，这些化合物含有临床批准的药物和人类细胞系中的生物活性化合物，包括甲状腺癌和肾上腺皮质癌。我们在筛选的一组甲状腺癌细胞系中鉴定了100种泛活性化合物，并且迄今为止已经鉴定了5种化合物，这些化合物在我们的临床前研究中具有有希望的结果，使用我们分支开发的转移性甲状腺癌小鼠模型。CUDC-907是一类组蛋白脱乙酰酶和磷脂酰肌醇3-激酶的双重抑制剂，是这些化合物之一。我们发现显着抑制生长和转移的6甲状腺癌细胞起源于低分化甲状腺癌和甲状腺未分化癌。从机制上讲，CUDC-907诱导半胱天冬酶依赖性细胞凋亡和G2 M阻滞，这与p21表达增加有关，并降低N-钙粘蛋白和波形蛋白表达水平。从我们使用4，292种化合物的药物库在3种肾上腺皮质癌细胞系中进行的高通量筛选中，我们鉴定了40种泛活性化合物。基于IC 50、血清可达浓度和药物疗效80%（与四辛基溴化铵相比）进行过滤，我们对氯硝柳胺的3种候选药物进行了随访研究，显示了我们临床前研究中的最佳结果，并有效靶向了肾上腺皮质癌中常见的遗传驱动事件和信号传导改变。我们在研究中取得的另一个进展是一个评估新型金纳米药物的临床前合作项目。在我们的甲状腺癌转移模型中，这种纳米药物显著降低了生长和转移，增加了总生存率，并诱导了细胞凋亡和肿瘤血管破坏。我们希望将来将这些发现转化为I/II期试验。

Background: Thyroid cancer: The incidence of thyroid cancer has doubled over the last two decades. Although most patients with thyroid cancer of follicular cell origin have an excellent prognosis, 10% - 15% will have refractory disease to conventional therapy (resection combined with radioiodine ablation and thyroid hormone for TSH suppression). Chemotherapy and external beam radiation are ineffective in patients with metastatic disease. The overall 10 year survival of patients with metastatic thyroid cancer of follicular cell origin is approximately 40-50%. Anaplastic thyroid cancer is one of the most lethal solid malignancies with no currently available effective systemic therapy. Adrenocortical carcinoma: Approximately two-thirds of patients who present with adrenocortical carcinoma have locoregional disease and metastasis. Unfortunately, despite combined multimodality therapy, the overall prognosis of patients with adrenocortical carcinoma remains dismal, with a 5-year survival of less than 35%. Summary: We have completed a quantitative high-throughput screening of 4,292 newly assembled compounds containing clinically approved drugs and bioactive compounds in human cell lines, including thyroid cancer and adrenocortical carcinoma. We identified 100 pan-active compounds in a panel of thyroid cancer cell lines screened and have thus far identified 5 compounds with promising results in our preclinical studies, using a mouse model of metastatic thyroid cancer developed in our branch. CUDC-907, a first-in-class dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase, is one of these compounds. We found significant inhibition of growth and metastases in 6 thyroid cancer cells originating from poorly differentiated thyroid cancer and anaplastic thyroid cancer. Mechanistically, CUDC-907 induced caspase-dependent apoptosis and G2M arrest that was associated with increased p21 expression, and reduced N-cadherin and vimentin expression levels. From our high-throughput screening in 3 adrenocortical carcinoma cell lines using a drug library of 4,292 compounds, we have identified 40 pan-active compounds. Filtering based on IC50, serum achievable concentration, and drug efficacy 80% (as compared to tetraoctylammonium bromide), we have performed follow up studies in 3 drug candidates with niclosamide showing the best results in our preclinical studies and also effectively targeting genetic driver events and signaling alterations common in adrenocortical carcinoma. Another progress we have made in our studies is a collaborative preclinical project evaluating a novel gold nanomedicine. This nanomedicine significantly reduced growth and metastasis, increased overall survival, and induced apoptosis and tumor vascular disruption in our metastatic model of thyroid cancer. We hope to translate these findings into Phase I/II trial in the future.